Just as working from home has become the “new normal,” clinical trials have had to adapt to pandemic restrictions that prevented the collection of data in the standard way. From local safety orders to the fear participants have when leaving their home, trial protocols were strained. Some trials paused or were canceled, while others found innovative ways to continue their studies in this “new normal.”
Register for this webinar to hear an expert from Egnyte discuss what clinical trials will look like once safety restrictions have been lifted, which trends from the COVID-19 pandemic will be carried forward and which will not, and who the leaders will be when trials resume.
James Allgood, Product Marketing, Life Sciences, Egnyte
James has over 20 years of experience within heavily regulated industries like finance, food and pharma. He enjoys pushing the boundaries of new technologies by introducing them into the life sciences to improve quality and lower costs. James earned his Bachelor of Science in Ecology and Evolutionary Biology from the University of Arizona and his MBA from Holy Names University. He lives and works in beautiful Oakland, California.Message Presenter
Who Should Attend?
- Data Management
- Clinical Operations
- Regulatory Affairs
What You Will Learn
Participants will hear about Egnyte’s predictions for when trials return to “normal”:
- What will clinical trials look like after the safety restrictions are lifted?
- Which trends will be discontinued, and which should remain
- Who will be calling the shots when trials start up again?
Egnyte is the only secure content platform built specifically for business. With thousands of customers worldwide, in a variety of different vertical markets, Egnyte delivers secure content collaboration, compliant data protection and simple infrastructure modernization; all through a single SaaS platform. Founded in 2007, Egnyte is a privately held company with headquarters in Mountain View, CA, and offices in Raleigh, NC, Spokane, WA, London, and Poland. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.